Coherus Oncology to Report Second Quarter 2025 Financial Results on August 7, 2025

Financial Results Announcement - Coherus Oncology will release its second quarter 2025 financial results after market close on August 7, 2025 [1] - A conference call and webcast will be hosted by Coherus' management team starting at 5:00 p.m. EDT on the same day to discuss the financial results and provide a business update [1][3] Webcast and Access Information - A replay of the webcast will be available on the Coherus investor website following the live conference call [2] - The press release with the financial results and related materials will be accessible on the investor website before the conference call begins [3] Company Overview - Coherus Oncology is a fully integrated commercial-stage innovative oncology company with an approved PD-1 inhibitor, LOQTORZI, and a promising pipeline including two mid-stage clinical candidates targeting various cancers [6] - The company aims to grow sales of LOQTORZI in nasopharyngeal carcinoma and advance new indications in combination with pipeline candidates and partners [6] Pipeline and Research Focus - Coherus' pipeline includes multiple antibody immunotherapy candidates designed to enhance immune responses against tumors [7] - CHS-114, a selective anti-CCR8 antibody, is in Phase 1b studies for advanced solid tumors, while Casdozokitug, an IL-27 antagonistic antibody, is being evaluated in multiple studies for various cancers [7]